Moderna, Inc. (NASDAQ:MRNA) Shares Sold by Mutual of America Capital Management LLC

Mutual of America Capital Management LLC reduced its position in shares of Moderna, Inc. (NASDAQ:MRNA) by 4.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 44,357 shares of the company’s stock after selling 1,948 shares during the period. Mutual of America Capital Management LLC’s holdings in Moderna were worth $4,411,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Vanguard Group Inc. increased its position in Moderna by 0.7% during the third quarter. Vanguard Group Inc. now owns 27,658,449 shares of the company’s stock worth $2,856,841,000 after purchasing an additional 196,012 shares during the last quarter. Geode Capital Management LLC increased its position in Moderna by 1.3% during the first quarter. Geode Capital Management LLC now owns 6,244,957 shares of the company’s stock worth $957,063,000 after purchasing an additional 77,265 shares during the last quarter. Wellington Management Group LLP increased its position in Moderna by 9.3% during the third quarter. Wellington Management Group LLP now owns 5,611,119 shares of the company’s stock worth $579,572,000 after purchasing an additional 476,201 shares during the last quarter. Morgan Stanley increased its position in Moderna by 19.1% during the fourth quarter. Morgan Stanley now owns 4,187,353 shares of the company’s stock worth $752,133,000 after purchasing an additional 670,284 shares during the last quarter. Finally, The Manufacturers Life Insurance Company increased its position in Moderna by 77.3% during the third quarter. The Manufacturers Life Insurance Company now owns 3,876,147 shares of the company’s stock worth $400,367,000 after purchasing an additional 1,690,341 shares during the last quarter. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms recently issued reports on MRNA. William Blair restated a “market perform” rating on shares of Moderna in a research report on Monday, April 1st. Jefferies Financial Group reiterated a “buy” rating and set a $125.00 price target on shares of Moderna in a research report on Tuesday, April 9th. HSBC reiterated a “reduce” rating and set a $86.00 price target (up from $75.00) on shares of Moderna in a research report on Monday, February 26th. Oppenheimer upgraded shares of Moderna from a “market perform” rating to an “outperform” rating and set a $142.00 price target for the company in a research report on Tuesday, January 2nd. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $125.00 price target on shares of Moderna in a research report on Thursday, March 28th. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $126.49.

Moderna Trading Down 1.2 %

Shares of MRNA stock opened at $103.86 on Tuesday. Moderna, Inc. has a fifty-two week low of $62.55 and a fifty-two week high of $156.75. The company has a 50 day moving average price of $99.86 and a 200 day moving average price of $93.49. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.36 and a current ratio of 3.42. The stock has a market capitalization of $39.77 billion, a P/E ratio of -8.37 and a beta of 1.62.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings results on Thursday, February 22nd. The company reported $0.55 EPS for the quarter, topping the consensus estimate of ($0.78) by $1.33. Moderna had a negative net margin of 68.84% and a negative return on equity of 10.23%. The company had revenue of $2.80 billion during the quarter, compared to analysts’ expectations of $2.53 billion. During the same quarter in the previous year, the business posted $3.61 EPS. The firm’s revenue was down 44.9% on a year-over-year basis. Equities research analysts predict that Moderna, Inc. will post -7.48 EPS for the current fiscal year.

Insiders Place Their Bets

In other Moderna news, Director Noubar Afeyan sold 15,000 shares of the business’s stock in a transaction that occurred on Wednesday, April 10th. The shares were sold at an average price of $107.12, for a total transaction of $1,606,800.00. Following the completion of the transaction, the director now owns 2,071,931 shares in the company, valued at approximately $221,945,248.72. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other news, insider Shannon Thyme Klinger sold 670 shares of the company’s stock in a transaction on Thursday, February 29th. The shares were sold at an average price of $94.57, for a total value of $63,361.90. Following the completion of the transaction, the insider now owns 8,557 shares in the company, valued at approximately $809,235.49. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, Director Noubar Afeyan sold 15,000 shares of the stock in a transaction on Wednesday, April 10th. The stock was sold at an average price of $107.12, for a total transaction of $1,606,800.00. Following the sale, the director now owns 2,071,931 shares of the company’s stock, valued at approximately $221,945,248.72. The disclosure for this sale can be found here. Insiders sold 79,954 shares of company stock worth $8,407,976 in the last 90 days. Corporate insiders own 15.20% of the company’s stock.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.